Another relative newcomer to the Dublin market, Galen Pharmaceuticals, is being seen as a stock that could provide handsome gains for investors in the longer term.

Since the flotation the shares have slipped back a bit but analysts believe its prospects are very bright. In a recent report Goodbody Stockbrokers says it sees little downside in the short-to-medium term for the company.

The Northern Ireland-based firm has been in business for almost 30 years. Next week, investors will get a glimpse at its first full-year performance since flotation. The results are expected to be at least within brokers' forecasts and possibly ahead. They should remember, however, that Galen is seen as a relatively high-risk stock, which will have to deliver significant growth to justify the high market rating for its shares.